Phase 2 N=474 A Study of Atezolizumab in Advanced Solid Tumors
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Phase 2 N=16 Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Solid Tumor, Adult
Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants
Phase 1 N=19 Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Phase 2 N=130 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
N/A N=21 Molecular and Whole-body MR Imaging in Lymphomas
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Phase 2 N=93 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Phase 1 N=147 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
N/A N=20 The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Renal Cancer · Tumor, Solid · Kidney Cancer
Primary: Primary Effectiveness: Technical Success — 100.0 percentage of tumors
Phase 2 N=29 M6620 (VX-970) in Selected Solid Tumors
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Phase 2 N=12 Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Phase 2 N=30 Phase 2 Study of ONC201 in Neuroendocrine Tumors
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Phase 2 N=223 Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent…
N/A N=12 Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
Cervical · Ovarian · Lung
Primary: Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition — 71.9 percent increase sestamibi retention
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 1 N=3 C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose
Phase 2 N=8 Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Phase 1 N=65 Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
Sarcoma, Ewing's
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 participants
Phase 2 N=24 A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Rhabdomyosarcoma · Melanoma
Primary: Average Number of Lymph Nodes Identified Intraoperatively Per Subject — 3.30 nodes per subject
Phase 2 N=50 Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 1 N=23 A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Solid Tumors
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 2 Participants